内皮素受体阻滞剂在糖尿病并发症中的应用  

Application of endothelin receptor antagonists in diabetic complication

作　　者：高锋[1] 梁远军[1] 董俊军[1] 刘克良[1] 

机构地区：[1]军事医学科学院毒物药物研究所,北京100850

出　　处：《中国新药杂志》2007年第19期1552-1556,共5页Chinese Journal of New Drugs

基　　金：北京市科委创新药物研究开发资助项目(D0206001040691);全军医药卫生科研基金课题(06z60)

摘　　要：内皮素是目前已知的缩血管活性最强的生物活性肽之一,通过与内皮素受体结合发挥广泛的生物学活性。内皮素的异常表达与肺动脉高压、前列腺癌、慢性心力衰竭等多种疾病的发生和发展有密切关系。近年来又有大量研究证实内皮素与糖尿病并发症的发生、发展有着重要的关系,内皮素受体阻滞剂可能成为糖尿病并发症治疗的新型药物。现综述内皮素受体阻滞剂在糖尿病并发症中的应用。Endothelin is one of the most potent vasoconstriction peptides, and it plays importantphysiological role by interacting with its receptors. Its abnormal level participates in the pathogenesis of pulmonary artery hypertension, carcinoma of prostate and chronic cardiac failure. A lot of recent experimental data showed that endothelin participated in the pathogenesis of diabetic complication, so endothelin receptor antagonists may become the new drug for the treatment of diabetic complication. This paper reviewed recent progress in the application of endothelin receptor antagonists in diabetic complication.

关 键 词：内皮素 内皮素受体阻滞剂 糖尿病并发症 

分 类 号：R977.6[医药卫生—药品]